Daily Intelligence Brief
Daily Docket: Depo-Provera, Hair Relaxer, and Uber Assault Drive 59 New Filings
LexGenius tracked 59 new federal filings over the past day, with pharmaceutical, cosmetic, and institutional accountability dockets setting the pace. The Depo-Provera Products Liability Litigation (MDL 3140) led with 12 new suits, spearheaded by Wright & Schulte LLC and Johnson Law Group. The Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) posted 10 new cases, driven by Morgan & Morgan PA and Douglas & London. The Uber Technologies, Inc., Passenger Sexual Assault Litigation (MDL 3084) added 9 new complaints paced by Levin Simes LLP and Wagstaff Law Firm, while the Paraquat Products Liability Litigation (MDL 3004) saw Hochman Law Firm PLLC file 5 new actions. Krentsel & Guzman LLP contributed 3 complaints to the Aqueous Film-Forming Foams Products Liability Litigation (MDL 2873), and Flint Cooper advanced claims in both the Glucagon-like Peptide-1 Receptor Agonists Gastroparesis Litigation (MDL 3094) and the Glucagon-like Peptide-1 Receptor Agonists NAION Litigation (MDL 3163).Uber Sexual Assault MDL Secures Non-Delegable Duty Ruling as Second Bellwether Returns $5,000 Split Verdict
The Uber Technologies, Inc., Passenger Sexual Assault Litigation (MDL 3084) hit a pair of procedural inflection points yesterday as a San Francisco jury delivered a $5,000 verdict in the second bellwether trial and presiding Judge Charles Breyer ruled that Uber owes passengers a non-delegable duty of care for driver conduct. The modest damages figure — a sharp pullback from the $8.5 million first-bellwether award — reflects jury disagreement on the plaintiff's specific compensatory theory rather than a liability acquittal, as the panel still found Uber responsible for the underlying assault. The non-delegable duty ruling functionally forecloses Uber's independent-contractor defense across the remaining roughly 3,300 federal actions and eliminates one of the company's core legal shields heading into the third bellwether. Practitioners should expect renewed mediation pressure even as the split damages record complicates any global-settlement valuation anchored to the first-bellwether number.Bayer Floats Roundup Global Resolution as New Jersey MCL and U.S. Supreme Court Preemption Question Loom
Bayer AG is circulating a proposed global resolution of remaining Roundup Products Liability claims as the glyphosate-cancer litigation approaches two potentially defining venues — New Jersey's Multicounty Litigation docket and a pending U.S. Supreme Court cert petition that could reshape federal preemption doctrine under FIFRA, according to an April 16 National Law Review analysis. The proposed framework would consolidate outstanding federal and state exposures after more than $11 billion in prior settlement payouts, with Bayer executives signaling that a definitive end to Roundup litigation remains a strategic priority for the 2026 fiscal year. A favorable SCOTUS ruling on EPA-label preemption could gut plaintiffs' failure-to-warn theory across pending cases, while an adverse decision — or a denied cert — would likely force Bayer to accept richer settlement terms. Firms holding Roundup inventory should calibrate claim-acceptance and valuation windows around the Court's conference calendar and Bayer's Q2 disclosures.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
